Recognizing Medical Necessity for iDose TR

iDose TR (travoprost intracameral implant) 75 mcg

Document the rationale for the treatment choice

Non-compliant/non-adherent to topical glaucoma medications

Uncontrolled on topical glaucoma medication(s)

Intolerant or allergic to topical medication(s)

Underlying co-morbidities (e.g. ocular surface disease)

Experienced side effects on topical medications that have affected quality of life

Underwent prior intervention and remain in need of therapy

Have questions, or need extra assistance? Contact your local Reimbursement Liaison.

For patients with Commercial insurance or Medicare Advantage plans, a prior authorization is necessary to ensure coverage for iDose TR.

Indications And Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) orocular hypertension (OHT).

Important Safety Information

Dosage and Administration
For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications
iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions
iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions
In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please See Full Prescribing Information.
You are encouraged to report all side effects to the FDA.
Visit **www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.**

iDose® *TR*